Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

177.82 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	369
Open	177.82
Bid (Size)	174.08 (100)
Ask (Size)	177.27 (100)
Prev. Close	177.82
Today's Range	177.82 - 177.82
52wk Range	110.03 - 185.17
Shares Outstanding	145,800,000
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

The Great Decoupling: How the AI Monetization Era Reshaped the Nasdaq in 2025

December 26, 2025

As of December 26, 2025, the Nasdaq Composite and Nasdaq-100 have reached historic milestones, closing out a year defined by the transition from artificial intelligence speculation to concrete...

Via MarketMinute

Biogen Inc. (NASDAQ:BIIB) Shows Strong Technical Setup for Potential Breakout ↗

December 26, 2025

Biogen (BIIB) shows a strong technical uptrend and a high-quality consolidation pattern, signaling a potential breakout opportunity for technical traders.

Via Chartmill

Performance

YTD	N/A	N/A
1 Month	-1.9%	-1.9%
3 Month	+15.4%	+15.4%
6 Month	+36.6%	+36.6%
1 Year	+16.0%	+16.0%

More News

The Trillion-Dollar Pharma: A Deep Dive into Eli Lilly’s (LLY) Dominance in the Weight-Loss Era

December 25, 2025

Via PredictStreet

The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS

December 22, 2025

From Biogen Inc.

Via GlobeNewswire

Therapeutics Stocks Q3 In Review: Biogen (NASDAQ:BIIB) Vs Peers

December 21, 2025

Via StockStory

Biogen (BIIB) Stock Trades Up, Here Is Why

December 19, 2025

Via StockStory

$7 Trillion "Witching Hour": Unprecedented Derivatives Expiration Sparks Volatility on Wall Street

December 19, 2025

Via MarketMinute

1 Nasdaq 100 Stock Worth Your Attention and 2 Facing Headwinds

December 18, 2025

Via StockStory

3 Healthcare Stocks We Think Twice About

December 10, 2025

Via StockStory

What's going on in today's session: S&P500 gap up and gap down stocks ↗

December 10, 2025

Via Chartmill

1 S&P 500 Stock to Keep an Eye On and 2 Facing Headwinds

December 07, 2025

Via StockStory

Is Alnylam Pharmaceuticals a Millionaire Maker? ↗

December 07, 2025

Via The Motley Fool

This Pharmaceutical Giant Fell by 10% After a Setback: Time to Sell the Stock? ↗

December 05, 2025

Via The Motley Fool

Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

December 05, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

December 05, 2025

From Biogen Inc.

Via GlobeNewswire

Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

December 01, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Novo Nordisk Shares Plunge as Alzheimer's Drug Trial Fails to Meet Primary Endpoint

November 24, 2025

Via MarketMinute

Which S&P500 stocks are moving before the opening bell on Monday? ↗

November 24, 2025

Via Chartmill

Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions

November 24, 2025

From Biogen Inc.

Via GlobeNewswire

AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know

November 21, 2025

Via StockStory

Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference

November 20, 2025

From Biogen Inc.

Via GlobeNewswire

Uncover the latest developments among S&P500 stocks in today's session. ↗

November 18, 2025

Via Chartmill

Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

November 17, 2025

From Biogen Inc.

Via GlobeNewswire

High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy

November 17, 2025

From Biogen Inc.

Via GlobeNewswire

Biogen Completes Acquisition of Alcyone Therapeutics

November 14, 2025

From Biogen Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Biogen Idec publicly traded?

Yes, Biogen Idec is publicly traded.

What exchange does Biogen Idec trade on?

Biogen Idec trades on the Nasdaq Stock Market

What is the ticker symbol for Biogen Idec?

The ticker symbol for Biogen Idec is BIIB on the Nasdaq Stock Market

What is the current price of Biogen Idec?

The current price of Biogen Idec is 177.82

When was Biogen Idec last traded?

The last trade of Biogen Idec was at 01/02/26 04:00 PM ET

What is the market capitalization of Biogen Idec?

The market capitalization of Biogen Idec is 25.93B

How many shares of Biogen Idec are outstanding?

Biogen Idec has 26B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.